TH-MYCN tumors, but not tumor-derived cell lines, are adrenergic lineage, GD2+, and responsive to anti-GD2 antibody therapy. - McNerney, K. O.; Karageorgos, S.; Ferry, G. M.; Wolpaw, A. J.; Burudpakdee, C.; Khurana, P.; Toland, C. N.; Vemu, R.; Vu, A.; Hogarty, M. D.; Bassiri, H. (OncoImmunology, 2022)